Linkedin X-twitter Youtube
Launch Digital Edition

Webinars and Sponsored Roundtables — Register Now

Tuesday, April 28, 2026, 12:00 PM–1:00 PM ET
Discover how next-day comprehensive genomic profiling (CGP) is possible with the Oncomine Comprehensive Assay Plus on the Genexus System—delivering both speed and accuracy.

Webinar presenters Jane Bayani, MHSc, PhD, Assistant Professor and Co-Director, Diagnostic Development, Ontario Institute for Cancer Research, Canada, and Nicola Normanno, MD, Scientific Director, IRCCS Romagnolo Institute for the Study of Tumors, Italy, and Morten Grauslund, PhD, Molecular Biologist, Department of Pathology, Rigshospitalet/Copenhagen University Hospital, Copenhagen, Denmark.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Thermo Fisher Scientific. For Research Use Only. Not for use in diagnostic applications. 

Register Now

Thursday, April 30, 2026, 11:00 AM–12:00 PM ET
Hear an expert discuss how Memorial Sloan Kettering Cancer Center (MSKCC) is utilizing
the oncoReveal® Nexus 21-gene panel to redefine turnaround time and actionable insights
in cancer care. Dr. Ewalt shares a perceptive look at the clinical need for rapid, front-line NGS sequencing, and how a unique, purpose built targeted NGS panel (Pillar Biosciences’ oncoReveal Nexus 21 gene Panel) was developed, validated and implemented clinically by Memorial Sloan Kettering Cancer Center (MSK-REACT) to complement their current comprehensive genomic profiling (CGP) approach.

Webinar presenter Mark Ewalt, MD, Associate Medical Director for Laboratory Operations for Diagnostic Molecular Pathology in the Molecular Diagnostics Service, Department of Pathology and Laboratory Medicine, MSKCC.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Pillar Biosciences.

Register Now

Thursday, May 28, 2026, 1:00–2:00 PM ET
This session is designed to improve understanding and application of recent updates to synoptic pathology reporting protocols such as the latest Reporting Template for Reporting Results of Biomarker Testing of Specimens from Patients with Carcinoma of the Breast. These changes reflect evolving clinical guidelines that directly influence diagnostic accuracy and treatment selection in breast cancer care.

Webinar presenters Thaer Khoury, MD, FCAP, Chair, Pathology and Laboratory Medicine, Roswell Park Comprehensive Cancer Cente, and Colin Murphy,  CEO of mTuitive.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Subspecialties

Interactive Product Guides

2025 Issues

Put It on the Board

September 2025—CAP president Donald Karcher, MD, in a July 25 letter urged the chairs and ranking members of the Senate and House appropriations subcommittee on labor, health and human services, education, and related agencies to apply pressure to obligate and award already approved funding for the CDC Division of Cancer Prevention and Control. “Even though Congress approved FY 2025 funding in March, the CDC has not issued notice of awards to provide funding to state and local health departments for the remaining FY 2025 funds,” he said. “State and local health departments are challenged to continue their work without knowing if they will be reimbursed. State health departments and grantees are on the verge of shutting down programs and furloughing staff.”

Letters

September 2025—It has come to the attention of the American Association of Pathologists’ Assistants that some pathologists and pathology fellows assume the pathologists’ assistant profession is widely licensed, since we are comparable to the nationally licensed physician associates. This is a misconception that I, chair of the AAPA legislative subcommittee, and the AAPA Board of Trustees would like to address with the pathology community.

Big interest, gaps in early pancancer testing

August 2025—There’s the cart before the horse. There are certain equines that should not be flogged; others should not be backed. There’s closing the stable door at an unfortunate time.

The fine points of NIFTP interpretation

August 2025—The noninvasive follicular thyroid neoplasm with papillary-like nuclear features, or NIFTP, is an entity that was introduced nearly a decade ago. It’s a lesion no longer considered malignant and instead grouped with more indolent lesions, owing to its observed indolent clinical behavior.

Study reveals extrachromosomal DNA’s impact

August 2025—Detection of extrachromosomal DNA in a tumor was found in a study published late last year to be associated with tumor stage, more prevalent after targeted and cytotoxic therapy, and associated with metastases and shorter overall survival.

Capillary and venous blood equivalence studied for routine tests

August 2025—For routine diagnostic testing, capillary blood is a reliable alternative to venous blood, say the authors of a study published in May. The study was led by Babson Diagnostics, of Austin, Tex., an independent startup spun out of Siemens Healthineers. Babson says it’s the first to validate capillary blood as a viable option for routine testing.

D-dimer reporting, INR among the variables that matter

August 2025—Anticoagulant interference, INR calculation, and D-dimer reporting are among the coagulation testing analytical and postanalytical variables that merit caution. Andrew Goodwin, MD, and Eric Salazar, MD, PhD, in a CAP24 session dug into why and what the requirements are, including for viscoelastic testing.

The man to match the times

August 2025—The Dark Intelligence Group, led by its founder and CEO Robert Michel, announced in March it had sold its information services assets to LabX Media Group of Midland, Ontario, Canada, led by CEO Bob Kafato. Among these assets are The Dark Report, DarkDaily ebriefings, and events such as the annual Executive War College. Thus it is that Michel begins his exit from the laboratory field and his path to retirement. CAP TODAY publisher Bob McGonnagle and editor Sherrie Rice spoke with Michel in May about the sale and his decades at the helm of an intelligence service that many in clinical and anatomic pathology labs and in industry turned to for the news and the experiences of early adopters. Here’s what he told us.

Labs talk budgets, AI, and care gaps and delays

August 2025—With cuts to government programs underway or on the way, how are laboratory budgets affected? CAP TODAY publisher Bob McGonnagle asked members of the Compass Group what the impact has been as of July 1, when the group met online. Also up: how one lab is gearing up to close two patient care gaps and using a Costco approach to do so.

A blood management road map in WHO’s latest guidance

August 2025—The World Health Organization released new guidance this spring to provide aid in implementing patient blood management programs and toolkits to support blood health and patient safety at various resource levels. “It’s the job of the clinician to make the right decisions about blood use at the right time. Patient blood management programs help them do that,” says Sherri Ozawa, MSN, RN, a coauthor of the WHO guidance. “What documents like this and others do is help make the bridge between what laboratory professionals already know and changing clinical practice.” Ozawa is director of patient blood management operations for hc1 of Indianapolis, Ind., a company that optimizes laboratory data to improve clinical practice, enabling better patient care, streamlining operations, and reducing costs.

MARKETPLACE

TRENDING